Michael Hooker

Scientists Create Non-Psychedelic Compound with Same Anti-depressant Effect

Retrieved on: 
Wednesday, September 28, 2022
Mental Health, Research, Other Natural Resources, Other Health, Alternative Medicine, Health, Other Science, Science, Natural Resources, Tao, Selective serotonin reuptake inhibitor, National, Depression, Human, THP, LSD, DARPA, Patient, UNC, 5-HT2A, R-69, Anxiety, Research, Hallucination, Psychiatry, Eugene Higgins, Mouse, Serotonin, Doctor of Philosophy, DMT, Â, UCSF, Duke, Ketamine, Michael Hooker, FDA, MD, UNC School of Medicine, University of North Carolina at Chapel Hill, Stanford University, AstraZeneca, Permeability, Tony Hawk's Pro Skater 1 + 2, Department, Mount Sinai, Brain, Zehnder Confair, Psilocybin, Esketamine, Ellman, Neurochemistry, Defense, University of California, San Francisco, Protein, Cell, N,N-Dimethyltryptamine, Substance abuse, SSRI, Department of Defense Office of Inspector General, Multimedia, Neuron, Pharmaceutical industry, Yale University, Medicine, Pharmacology, Chemistry, Nature

Some advocates and scientists believe the actual psychedelic trip hallucinations and profound emotional experiences is what leads to long-lasting therapeutic effects.

Key Points: 
  • Some advocates and scientists believe the actual psychedelic trip hallucinations and profound emotional experiences is what leads to long-lasting therapeutic effects.
  • Other scientists speculate that if the trip could be eliminated from such drugs, then only the therapeutic effects might remain.
  • We were basically running a chemistry experiment to see if we could create a compound to activate 5-HT2A.
  • It would be a game changer to create a one-dose, long-acting therapy to help people with treatment-resistant depression and other conditions.

MindMed Appoints University of North Carolina Psychiatrist and Pharmacologist Dr. Bryan Roth to Scientific Advisory Board

Retrieved on: 
Wednesday, September 29, 2021
UNC School of Medicine, Nature, Duke University, Michael Hooker, University, Mental health, Stanford University, Johns Hopkins University, Cell, Psychiatry, DARPA, Industry, University of North Carolina at Greensboro, Biotechnology, News, Coronavirus Scientific Advisory Board (Turkey), Compliance, National, School, U.S. Securities and Exchange Commission, Multimedia, Ibogaine, Department of Pharmacology, University College London, NEO Exchange, Knowledge, Ultra-large-scale systems, MMQ, History, EDGAR, Clinical trial, Risk, NASDAQ, New York University, Company, SEDAR, National Institute, Brain, UNC, Neuroscience, NEO, Doctor of Philosophy, Massachusetts General Hospital, Department, LSD, Patient, MD, MDMA, DE, DMT, View, Research, Psilocybin, Hallucination, Pharmaceutical industry

He is the Michael Hooker Distinguished Professor in the Department of Pharmacology at the University of North Carolina's (UNC) School of Medicine.

Key Points: 
  • He is the Michael Hooker Distinguished Professor in the Department of Pharmacology at the University of North Carolina's (UNC) School of Medicine.
  • MindMed CEO Robert Barrow said, "We are thrilled to welcome Dr. Roth to our Scientific Advisory Board.
  • MindMed's Scientific Advisory Board is composed of a diverse group of members with expertise in psychiatry, neuroscience, and clinical development.
  • Members represent institutions such as Johns Hopkins University, New York University Langone Health, Duke University, the National Institutes of Health, Stanford University, and Massachusetts General Hospital.